Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
NCT06541314
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Fluzoparib
Sponsor
Qilu Hospital of Shandong University